We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Vaccine Could Simultaneously Target Multiple Viral Infections

By LabMedica International staff writers
Posted on 26 Sep 2017
Print article
Image: The human leukocyte antigen (HLA) ligand for a Killer-cell immunoglobulin-like receptor (KIR) (Photo courtesy of Wikimedia Commons).
Image: The human leukocyte antigen (HLA) ligand for a Killer-cell immunoglobulin-like receptor (KIR) (Photo courtesy of Wikimedia Commons).
A novel vaccine designed to prevent infection by several different viruses simultaneously in based on ability of a receptor protein on the surface of immune cells to recognize a common, invariable viral antigen.

Killer-cell immunoglobulin-like receptors (KIRs), are a family of type I transmembrane glycoproteins expressed on the plasma membrane of natural killer (NK) cells and a minority of T-cells. These receptors regulate the killing function of these cells by interacting with major histocompatibility (MHC) class I molecules, which are expressed on all nucleated cell types. KIR receptors can distinguish between major histocompatibility (MHC) class I allelic variants, which allows them to detect virally infected cells or transformed cells. Most KIRs are inhibitory, suppressing the cytotoxic activity of their NK cell. Only a limited number of KIRs are activating, meaning that their recognition of MHC molecules activates the cytotoxic activity of their cell. As a result of KIR's role in killing unhealthy self-cells and not killing healthy self-cells, KIRs are involved in protection against and propensity to viral infection, autoimmune disease, and cancer.

Investigators at the University of Southampton (United Kingdom) worked with the killer cell immunoglobulin-like receptor KIR2DS2. They singled out this important receptor protein for further study after analyzing DNA from more than 300 patients exposed to the hepatitis C virus and finding that the KIR2DS2 receptor was associated with successfully clearing the virus. In addition, they showed that KIR2DS2 directly recognized viral peptides derived from conserved regions of the NS3 helicase enzyme from the flaviviral superfamily (hepatitis C virus, Zika virus, dengue virus, yellow fever virus, Japanese encephalitis virus, etc.) in the context of major histocompatibility complex class I.

The investigators reported in the September 15, 2017, online edition of the journal Science Immunology that the peptide LNPSVAATL from the hepatitis C virus (HCV) helicase bound the human leukocyte antigen (HLA) allele HLA-C*0102, leading to NK cell activation through engagement of KIR2DS2. However, while this region was highly conserved across HCV isolates, the sequence was not present in other flaviviral helicases. They then identified a distinct peptide, MCHAT, which was sensed by KIR2DS2 and was conserved in a number of flaviviruses including dengue, Zika, and yellow fever viruses.

Senior author Dr. Salim Khakoo, professor of hepatology at the University of Southampton, said, "The NS3 helicase protein could be the key in unlocking the defense of lethal viruses that affect so many people around the world. It is very exciting to discover that other viruses similar to hepatitis C, such as Zika virus, dengue virus, yellow fever virus, Japanese encephalitis virus and in fact all flaviviruses, contain a region within their NS3 helicase proteins that is recognized by exactly the same KIR2DS2 receptor. We believe that by targeting this NS3 helicase region, we could make a new type of vaccine based upon natural killer cells, which can be used to help protect people from these infections."

Related Links:
University of Southampton

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.